Asha Vasantrao Chate et al. / Chinese Journal of Catalysis 37 (2016) 1997–2002
1999
OH); 13C NMR (100 MHz, CDCl3): δ 192.6, 170.7, 155.4, 136.8,
130.6, 123.7, 115.2, 61.9, 47.1, 32.8. LC‐MS (ES+) m/z: 313.08
[M]+. Elemental analysis Calcd. for C17H15NO3S: C, 65.16; H,
4.82; N, 4.47; S, 10.23; Found: C, 65.22; H, 4.89; N, 4.40.
one (4l). 1H NMR (DMSO, 400 MHz): δ 2.50 (s, 3H, CH3),
3.76–3.92 (dd, overlapped, 2H, methylene), 4.92 (s, 2H, CH2),
5.75 (t, 1H, methine), 7.22–7.30 (dd, 2H, Ar–H), 7.74–8.10 (m,
5H, Ar–H); 13C NMR (100 MHz, CDCl3): δ 193.6, 170.9, 141.6,
137.8, 131.8, 127.6, 126.4, 59.9, 48.1, 32.1. LC‐MS (ES+) m/z:
318.15 [M+H]+. Elemental analysis Calcd. for C16H15NO2S2: C,
60.54; H, 4.76; N, 4.41; S, 20.20; Found: C, 60.60; H, 4.86; N,
4.31.
2‐(3‐Methoxyphenyl)‐3‐(2‐oxo‐2‐phenylethyl)thiazolidin‐4‐
1
one (4d). H NMR (DMSO, 400 MHz): δ 3.65–3.69 (dd, over‐
lapped, 2H, methylene), 3.79 (s, 3H, OCH3), 5.11 (s, 2H, CH2),
5.96 (t, 1H, methine), 6.85–7.09 (m, 3H, Ar–H), 7.17 (s, 1H,
Ar–H), 7.20–7.64 (m, 5H, Ar–H); 13C NMR (100 MHz, CDCl3): δ
193.6, 172.4, 159.0, 140.4, 134.8, 129.9, 127.3, 122.7, 120.8,
111.1, 63.4, 55.6, 48.4, 32.5. LC‐MS (ES+) m/z: 327.09 [M+H]+.
Elemental analysis Calcd. for C18H17NO3S: C, 66.03; H, 5.23; N,
4.28; S, 9.79; Found: C, 66.13; H, 5.300; N, 4.20.
3‐(2‐Oxo‐2‐phenylethyl)‐2‐(p‐tolyl)thiazolidin‐4‐one (4e).
1H NMR (DMSO, 400 MHz): δ 2.32 (s, 3H, CH3), 3.33–3.73 (dd,
overlapped, 2H, methylene), 4.85 (s, 2H, CH2), 5.75 (t, 1H, me‐
thine), 7.02–7.27 (m, 4H, Ar–H), 7.20–7.77 (m, 5H, Ar–H); 13C
NMR (100 MHz, CDCl3): δ 193.4, 170.9, 139.0, 135.8, 133.9,
127.9, 63.4, 48.4, 31.8, 22.7. LC‐MS (ES+) m/z: 312.10 [M+H]+.
Elemental analysis Calcd. for C18H17NO2S: C, 69.43; H, 5.50; N,
4.50; S, 10.30; Found: C, 69.49; H, 5.58; N, 4.42.
3‐(2‐Oxo‐2‐(p‐tolyl)ethyl)‐2‐phenylthiazolidin‐4‐one (4f).
1H NMR (DMSO, 400 MHz): δ 2.49 (s, 3H, CH3), 3.64–3.98 (dd,
overlapped, 2H, methylene), 4.27 (s, 2H, CH2), 5.82 (t, 1H, me‐
thine), 7.10–7.19 (m, 4H, Ar–H), 7.37–7.59 (m, 4H, Ar–H); 13C
NMR (100 MHz, CDCl3): δ 193.2, 171.4, 145.0, 142.2, 139.2,
133.1, 128.5, 127.0, 124.6, 63.5, 49.5, 32.8, 21.0. LC‐MS (ES+)
m/z: 312.12 ([M]+ & 310.31 [M–H]+. Elemental analysis Calcd.
for C18H17NO2S: C, 69.43; H, 5.50; N, 4.50; S, 10.30; Found: C,
69.53; H, 5.40; N, 4.30; S, 10.21.
2‐(4‐Chlorophenyl)‐3‐(2‐oxo‐2‐(p‐tolyl)ethyl)thiazolidin‐4‐
one (4h): 1H NMR (DMSO, 400 MHz): δ 2.50 (s, 3H, CH3),
3.75–3.98 (dd, overlapped, 2H, methylene), 4.85 (s, 2H, CH2),
5.79 (t, 1H, methine), 7.17–7.29 (m, 4H, Ar–H), 7.35–7.73 (m,
4H, Ar–H); 13C NMR (100 MHz, CDCl3): δ 193.3, 170.7, 142.7,
141.2, 131.9, 128.8, 126.9, 62.7, 49.4, 33.8, 21.8. LC‐MS (ES+)
m/z: 345.06 [M]+ & 347.31 ([M+2H]+. Elemental analysis Calcd.
for C18H16ClNO2S: C, 62.51; H, 4.66; N, 4.05; S, 9.27; Found: C,
62.59; H, 4.72; N, 4.00.
2‐(3‐Methoxyphenyl)‐3‐(2‐oxo‐2‐(p‐tolyl)ethyl)thiazolidin‐
4‐one (4i). 1H NMR (DMSO, 400 MHz): δ 2.49 (s, 3H, CH3),
3.72–3.78 (dd, overlapped, 2H, methylene), 3.92 (s, 3H, OCH3),
4.82 (s, 2H, CH2), 5.55 (t, 1H, methine), 6.59–6.89 (m, 3H,
Ar–H), 7.30 (s, 1H, Ar–H), 7.32–7.39 (m, 4H, Ar–H); 13C NMR
(100 MHz, CDCl3): δ 193.7, 170.7, 158.7, 141.3, 139.9, 131.9,
129.8, 127.9, 63.7, 55.4, 49.6, 33.1, 21.8. LC‐MS (ES+) m/z:
342.11 [M]+. Elemental analysis Calcd. for C19H19NO3S: C, 66.84;
H, 5.61; N, 4.10; S, 9.39; Found: C, 66.90; H, 5.70; N, 4.02.
3‐(2‐Oxo‐2‐phenylethyl)‐2‐(thiophen‐2‐yl)thiazolidin‐4‐one
(4j). 1H NMR (DMSO, 400 MHz): δ 2.56 (s, 3H, CH3), 3.79–3.96
(dd, overlapped, 2H, methylene), 4.84 (s, 2H, CH2), 6.16 (t, 1H,
methine), 6.94–6.96 (dd, 2H, Ar–H), 7.29–8.50 (m, 6H, Ar–H);
13C NMR (100 MHz, CDCl3): δ 193.4, 170.6, 139.5, 134.6, 133.7,
127.8, 126.6, 58.9, 49.5, 32.7. LC‐MS (ES+) m/z: 304.14 [M+H]+.
Elemental analysis Calcd. for C15H13NO2S2: C, 59.38; H, 4.32; N,
4.62; S, 21.14; Found: C, 59.48; H, 4.40; N, 4.52.
3. Results and discussion
Herein, we report a new convergent approach for the effi‐
cient and convenient synthesis of a novel series of thiazoli‐
dinone derivatives, which could be conveniently incorporated
into a wide range of different drug molecules. This type of con‐
vergent approach has several advantages over existing proce‐
dures, including using catalyst for accelerating cyclocondensa‐
tion N,N’‐dicyclohexylcarbodiimide (DCC), O‐(benzotriazol‐yl)‐
N,N,N’,N”‐tetramethyluronium hexafluoro phosphate (HBTU),
activated fly ash and the use of microwave heating. Although
several 2‐amino‐1‐phenylethanone hydrochlorides are known
in the literature, the reported syntheses of these compounds
generally require 2–3 h at room temperature and are formally
recognized as two‐step procedures [39,40]. To the best of our
knowledge, the 3‐(2‐oxo‐2‐phenylethyl)‐2‐phenylthiazolidin‐4‐
ones (4a–4m) reported in this study have not been reported
elsewhere in the literature to date.
Compounds 4a–4m were prepared from two slightly dif‐
ferent 2‐amino‐1‐phenylethanone hydrochloride salts, which
were themselves prepared from the corresponding phenacyl
chlorides according to a two‐step procedure. Thus, the De‐
lépine reaction [39] of the phenacyl chlorides with hexameth‐
ylenetetramine afforded the corresponding heximinium salts in
high yields (90%–92%), which were subsequently hydrolyzed
under acidic conditions to give the corresponding amines as the
hydrochloride salts (Scheme 1) [40]. These amine hydrochlo‐
ride salts were then treated with a series of benzaldehydes
(1a–1m) in the presence of N,N‐diisopropylethylamine
(DIPEA) to give the corresponding imines, which underwent a
cyclocondensation reaction with mercaptoacetic acid in toluene
at 110 °C to give the desired thiazolidinones 4a–4m (Scheme
2). Compound 4a was obtained in 48% yield when CH3CN was
Scheme 1. Synthesis of the substituted 2‐amino‐1‐phenylethanone
hydrochlorides 2a.
S
O
N
DIPEA
Toluene/3-4 h
R
R1
HS COOH
NH2HCl
R1
CHO
1a-1m
O
O
2a
3
R
R = H/CH3
4a-4m
Scheme 2. Synthesis of substituted 3‐(2‐oxo‐2‐phenylethyl)‐2‐phenyl‐
thiazolidin‐4‐one derivatives.
3‐(2‐Oxo‐2‐(p‐tolyl)ethyl)‐2‐(thiophen‐2‐yl)thiazolidin‐4‐